43.13
1.29%
0.55
After Hours:
42.20
-0.93
-2.16%
Legend Biotech Corp Adr stock is traded at $43.13, with a volume of 1.32M.
It is up +1.29% in the last 24 hours and down -3.60% over the past month.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
See More
Previous Close:
$42.58
Open:
$42.96
24h Volume:
1.32M
Relative Volume:
1.06
Market Cap:
$7.82B
Revenue:
$455.99M
Net Income/Loss:
$-285.01M
P/E Ratio:
-13.23
EPS:
-3.26
Net Cash Flow:
$-164.61M
1W Performance:
+7.45%
1M Performance:
-3.60%
6M Performance:
+4.15%
1Y Performance:
-29.94%
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Name
Legend Biotech Corp Adr
Sector
Industry
Phone
-
Address
-
Compare LEGN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
43.13 | 7.82B | 455.99M | -285.01M | -164.61M | -3.26 |
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-08-24 | Initiated | Redburn Atlantic | Buy |
Jun-17-24 | Initiated | Truist | Buy |
May-24-24 | Reiterated | H.C. Wainwright | Buy |
May-23-24 | Initiated | Deutsche Bank | Buy |
Apr-17-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
Apr-03-24 | Initiated | Cantor Fitzgerald | Overweight |
Mar-13-24 | Initiated | Raymond James | Outperform |
Dec-19-23 | Initiated | Scotiabank | Sector Perform |
Nov-06-23 | Initiated | Goldman | Buy |
May-25-23 | Initiated | William Blair | Mkt Perform |
May-22-23 | Initiated | Daiwa Securities | Buy |
Mar-29-23 | Initiated | H.C. Wainwright | Buy |
Mar-24-23 | Initiated | RBC Capital Mkts | Outperform |
Dec-06-22 | Initiated | UBS | Buy |
Nov-02-22 | Initiated | Evercore ISI | Outperform |
Nov-01-22 | Initiated | Cowen | Outperform |
Oct-31-22 | Initiated | Guggenheim | Neutral |
Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
Mar-15-22 | Initiated | Barclays | Overweight |
Jan-31-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Dec-21-21 | Initiated | Piper Sandler | Overweight |
May-18-21 | Initiated | BTIG Research | Buy |
Jul-01-20 | Initiated | JP Morgan | Overweight |
Jul-01-20 | Initiated | Jefferies | Buy |
Jun-30-20 | Initiated | Morgan Stanley | Overweight |
View All
Legend Biotech Corp Adr Stock (LEGN) Latest News
Earnings call: Legend Biotech sees strong growth with CARVICTI sales - Investing.com India
Legend Biotech Corp ADR (NASDAQ: LEGN) Has Great Upside Potential - Stocks Register
Thinking Of Investing In Bilibili Inc ADR (NASDAQ: BILI) Stock? Read This First - Stocks Register
Are Medtronic Plc (NYSE: MDT) Analysts Predicting A Spike? - Stocks Register
Why Is Legend Biotech Corporation (LEGN) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance
Parkway Corporate Limited Announces New Securities Issuance - MSN
Legend Biotech stock hits 52-week low at $38.59 amid market shifts - Investing.com
Legend Biotech's SWOT analysis: stock shows promise amid CAR-T therapy growth - Investing.com India
Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential - Investing.com India
Legend Biotech shares steady with Overweight rating as Cantor raises target on Carvykti potential By Investing.com - Investing.com South Africa
Earnings call: Legend Biotech sees robust growth in CARVYKTI sales - Investing.com
Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Legend Biotech's SWOT analysis: carvykti success drives stock outlook - Investing.com
Gilead Science to Report Q3 Earnings: What's in the Cards? - Yahoo Finance
Legend Biotech appoints new President for CARVYKTI - Investing.com
Legend Biotech Corp ADR (NASDAQ:LEGN) Stock Is up 15.91% From Its Low, This Stock Is Just Warming Up - Stocks Register
Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade - Yahoo Finance
Adma Biologics Inc (ADMA) Should Be Considered For The Next Few Weeks - Stocks Register
Legend Biotech shares hold Buy rating, $91 target despite Q3 CARVYKTI sales - Investing.com India
Legend Biotech shares hold as Barclays maintains $94 target - Investing.com India
Company’s Banking Stock: Dissecting a -18.35% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Redburn Atlantic initates Legend Biotech Corp ADR (LEGN) rating to a Buy - Knox Daily
Li Auto Inc ADR (LI) rating downgrades by Macquarie - Knox Daily
Recent Insider Activity Suggests Potential Gains for Enovix Corporation (ENVX) - Knox Daily
BMO maintains steady target on Legend Biotech on strong sales - Investing.com
BMO maintains steady target on Legend Biotech on strong sales By Investing.com - Investing.com South Africa
Stock Performance Spotlight: Legend Biotech Corp ADR (LEGN) Ends the Day at 49.68, Down by -0.64 - The Dwinnex
Legend Biotech Corp ADR’s results are impressive - US Post News
UnitedHealth, NVIDIA lead Tuesday's afternoon market cap stock movers By Investing.com - Investing.com UK
Legend Biotech maintains shares price target on steady Q3 growth - Investing.com
Legend Biotech Corp ADR’s Mixed Bag: Down -8.63% in 6 Months, Down 1.03% in 30 Days - The InvestChronicle
Market Insights: Legend Biotech Corp ADR (LEGN)’s Notable Gain of 1.62, Closing at 48.84 - The Dwinnex
Legend Biotech shares hold strong with positive outlook on robust Carvykti sales - Investing.com
Legend Biotech Corp ADR (LEGN) is a good investment, but the stock may be overvalued - US Post News
Redburn sees growth potential for Legend Biotech stock on Carvykti demand - Investing.com
Does Legend Biotech Corp ADR (LEGN) offer a good opportunity for investors? - SETE News
Legend Biotech stock maintains positive outlook with new Philadelphia R&D facility - Investing.com
Upward Trajectory: Legend Biotech Corp ADR (LEGN) Posts a Gaine, Closing at 48.68 - The Dwinnex
Legend Biotech Corp ADR (LEGN) stock analysis: A simple moving average approach - US Post News
You might want to take a look at Legend Biotech Corp ADR (LEGN) now - SETE News
Legend Biotech shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com South Africa
BMO maintains Outperform rating on Legend Biotech shares on Carvykti data - Investing.com India
Legend Biotech shares maintain Buy rating from H.C. Wainwright - Investing.com India
Legend Biotech's SWOT analysis: carvykti success drives stock potential - Investing.com
Legend Biotech reiterates stock target, overweight on Phase III data - Investing.com
Legend Biotech stock poised for growth with compelling data on Carvykti - Investing.com
Legend Biotech Corp ADR (LEGN) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Can you now get a good deal on Legend Biotech Corp ADR’s shares? - US Post News
Legend Biotech Corp Adr Stock (LEGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):